1. Introduction

The regulation of vulnerable population safeguards in biotechnology research in Morocco concerns the legal, ethical and institutional measures designed to protect individuals and communities who may face increased risks of exploitation, discrimination, coercion or physical and psychological harm during scientific research.

Vulnerable populations may include:

Children and minors participating in genetic or biomedical research.

Pregnant women and unborn children.

Persons with disabilities or limited decision-making capacity.

Economically disadvantaged individuals.

Patients suffering from serious or life-threatening diseases.

Refugees, migrants and socially marginalized communities.

Indigenous and local communities whose biological resources or traditional knowledge may be used in biotechnology research.

Individuals whose genetic, reproductive or biological information could expose them to discrimination.

In Morocco, these safeguards must be understood through constitutional protections, biomedical research legislation, personal-data protection, public-health regulation and international human-rights obligations.

A central legal principle is that scientific progress cannot justify treating vulnerable individuals merely as sources of biological materials or experimental data. Their dignity, autonomy, safety, privacy and rights must remain protected throughout the research process.

2. Constitutional and Human-Rights Framework

The Moroccan Constitution of 2011 provides the general foundation for protecting vulnerable research participants.

Important constitutional provisions include:

Article 20 – Right to Life

The right to life provides a constitutional foundation for protecting research participants against dangerous or unjustified experimental interventions.

Article 21 – Physical Integrity and Security

This provision protects individuals' physical integrity and security. It is particularly relevant to clinical trials, genetic interventions, experimental therapies and invasive biotechnology procedures.

Article 22 – Human Dignity and Bodily Integrity

Article 22 prohibits violations of physical or moral integrity and prohibits cruel, inhuman or degrading treatment. It is relevant when evaluating coercive experimentation, unauthorized biological interventions and abusive research practices.

Article 24 – Privacy

This provision protects private life, including aspects of personal and family privacy. Genetic information, reproductive information and identifiable biological records may fall within this protection.

Article 31 – Access to Healthcare

The State's responsibility to facilitate access to healthcare supports the development of research systems that do not exclude disadvantaged communities from potential medical benefits.

These provisions should be interpreted together. For example, obtaining consent from a patient does not automatically make a dangerous or degrading research intervention lawful.

3. Law No. 28-13 of 2015: Protection of Biomedical Research Participants

The most important legislation specifically governing this subject is Law No. 28-13 on the Protection of Persons Participating in Biomedical Research, promulgated by Dahir No. 1-15-110 of 4 August 2015.

It establishes a legal framework for protecting people participating in biomedical experiments and clinical research.

Article 3 identifies important principles governing biomedical research:

Respect for human life and health.

Protection of physical and psychological integrity.

Respect for human dignity and privacy.

Voluntary participation in research.

Free, informed and explicit consent.

Non-commercialisation of the human body.

Compliance with appropriate clinical and scientific standards.

These principles are particularly important where biotechnology research involves genetic modification, stem-cell treatments, experimental vaccines, reproductive technologies, biological samples and clinical trials.

The Moroccan Ministry of Health identifies Law No. 28-13 as part of the country's official medical-practice regulatory framework.

sante.gov.ma+1

3.1 Protection against exploitation

Researchers cannot treat economically disadvantaged patients as convenient experimental subjects merely because they are willing to participate in exchange for financial assistance or medical treatment.

Research participation must be genuinely voluntary. Investigators should ensure that financial incentives, dependence on healthcare providers or fear of losing access to treatment do not undermine free consent.

3.2 Protection against unnecessary medical risks

Research involving vulnerable participants must be scientifically justified and proportionate to the risks involved.

For example, a biotechnology company testing an experimental gene therapy on seriously ill patients should demonstrate:

A scientifically defensible research protocol.

Appropriate safety precautions.

Ethical review and regulatory authorization.

A justified risk-benefit assessment.

Appropriate medical supervision.

Procedures for responding to adverse events.

3.3 Special protection for minors and legally protected adults

Article 12 establishes particularly important safeguards.

Biomedical research involving minors or adults subject to a legal protection measure is generally permitted only where direct health benefits are expected and the legally prescribed consent of the representative has been obtained.

Research without direct therapeutic benefit may nevertheless be authorized, but only subject to strict conditions:

It must not present a foreseeable serious risk to the participant's health.

It must be useful to persons with comparable characteristics, such as age, illness or disability.

It must not be possible to conduct the research otherwise.

Where the participant is capable of expressing a will, their own free and informed consent must also be obtained. A refusal or withdrawal of consent cannot simply be overridden by the representative's approval.

Ma Loi

Example: A research institution wants to collect biological samples from children to investigate a rare genetic disorder. The parents' permission alone should not be treated as sufficient in every circumstance. The child's capacity to understand and express a preference must also be respected.

4. Informed Consent and Protection from Coercion

Informed consent is one of the most important legal safeguards in Moroccan biotechnology research.

Article 4 of Law No. 28-13 requires free, informed and express consent before biomedical research is conducted on an individual.

The researcher must provide information orally and through a written document in a language understood by the participant.

The information should explain:

The purpose of the research.

Its methodology and duration.

Foreseeable risks and constraints.

Expected benefits.

Available medical alternatives.

The participant's rights under the legislation.

The participant may seek assistance from a person of their choice to understand the information.

Where a clinical situation prevents prior consent, the legislation provides for consent from specified family members or a legal representative, subject to the statutory conditions. The participant must be informed as soon as their condition permits, and their consent becomes necessary for continuation of the research.

Ma Loi

Legal significance

Consent must not be confused with a signature on a research form.

A valid consent process requires:

Adequate disclosure.

Comprehension.

Voluntary decision-making.

Appropriate legal capacity or representation.

Respect for withdrawal.

This is especially important in genetic research because participants may not fully appreciate the consequences of discovering hereditary diseases, familial relationships or genetic predispositions.

5. Protection of Children in Biotechnology Research

Children require enhanced legal and ethical protection because their capacity to understand complex scientific procedures is developing.

Research involving children may include:

Genetic screening for hereditary diseases.

Stem-cell research.

Experimental vaccines.

Gene-therapy trials.

Paediatric clinical trials.

Research into inherited metabolic disorders.

Under Article 12 of Law No. 28-13, the distinction between research offering direct therapeutic benefits and research without direct therapeutic benefits is fundamental.

The following safeguards should be applied:

A. Parental or legal representative consent: The representative must receive sufficient information and provide consent in accordance with the law.

B. Child participation: A child capable of expressing a meaningful preference should be involved in the decision.

C. Respect for refusal: The child's refusal or withdrawal must not be disregarded merely because a parent has consented.

D. Risk limitation: Non-therapeutic research must satisfy the special statutory restrictions.

E. Future privacy: Genetic information collected during childhood should be protected against unnecessary disclosure and inappropriate future use.

An important difficulty concerns genetic testing that reveals information about relatives. A child's genetic profile may disclose risks affecting parents, siblings and future generations. Researchers must therefore consider familial confidentiality as well as the child's individual privacy.

6. Protection of Persons with Disabilities and Limited Decision-Making Capacity

Moroccan law must protect persons with disabilities against discrimination and exploitation in biomedical research.

The relevant constitutional and statutory principles include:

Equality and non-discrimination.

Human dignity.

Physical and psychological integrity.

Respect for personal autonomy.

Protection against involuntary experimentation.

Article 12 of Law No. 28-13 specifically addresses adults subject to legal protection measures.

The legal framework requires particular care in distinguishing legal representation from the participant's own ability to understand and express a decision.

For example, an adult with a cognitive disability may still be capable of understanding a particular research procedure. Disability alone should not automatically be treated as proof of incapacity.

Practical safeguards

Provide accessible consent documents.

Use simplified explanations where necessary.

Allow sufficient time for decision-making.

Avoid coercion by caregivers and institutional authorities.

Obtain the participant's own agreement wherever they can express it.

Respect refusal and withdrawal.

Ensure independent ethical assessment.

Morocco's obligations under the Convention on the Rights of Persons with Disabilities reinforce the importance of dignity, autonomy, accessibility and equal protection.

7. Protection of Prisoners and Institutionalised Persons

A particularly strong safeguard appears in Article 16 of Law No. 28-13.

The provision prohibits biomedical research on:

Persons deprived of liberty pursuant to a judicial decision.

Persons who have been compulsorily hospitalised.

Ma Loi

This prohibition is significant because people in detention or compulsory institutional settings may be exposed to pressure, dependency and limited freedom of choice.

For example, a biotechnology company cannot justify experimental vaccine research on a detained population simply by arguing that the participants are readily accessible.

The legal protection addresses the structural inequality between researchers and individuals whose freedom is restricted.

8. Protection of Pregnant Women and Unborn Children

Pregnant women may be involved in biotechnology research concerning:

Genetic screening during pregnancy.

Prenatal diagnostic technologies.

Experimental medicines.

Placental and fetal tissue research.

Reproductive biotechnology.

Maternal and fetal gene-related disorders.

Pregnancy creates additional ethical and legal considerations because research may affect both the woman and the developing fetus.

Moroccan constitutional protections concerning life, bodily integrity and dignity are relevant. Law No. 28-13's consent and risk-control requirements also apply to biomedical research involving pregnant participants.

The principal safeguards should include:

Separate assessment of maternal and fetal risks.

Clear explanation of possible pregnancy-related complications.

Voluntary informed consent.

Independent ethical examination.

Appropriate medical monitoring.

Protection against reproductive coercion.

Confidentiality of reproductive and genetic information.

A researcher should not assume that consent from a spouse or family member substitutes for the pregnant woman's own legally valid consent.

9. Genetic Privacy and Protection of Biological Information

Biotechnology research frequently involves highly sensitive personal information.

Examples include:

DNA sequences.

Genetic predispositions.

Hereditary disease information.

Reproductive genetic profiles.

Biological samples linked to identifiable individuals.

Genomic information collected from vulnerable communities.

Morocco's Law No. 09-08 on the Protection of Individuals with Regard to the Processing of Personal Data is especially important.

Article 1 expressly includes health information and genetic information within the category of sensitive personal data.

The legislation establishes requirements concerning lawful processing, specified purposes, proportionality, data accuracy and appropriate security.

It also provides for oversight by the National Commission for the Control of Personal Data Protection (CNDP).

BDJ+1

9.1 Genetic data and informed consent

Suppose a research organisation collects DNA samples from economically disadvantaged families to study hereditary diseases.

The organisation should explain:

Why the samples are being collected.

Which genetic tests will be conducted.

Whether the samples will be stored.

Whether identifiable information will be retained.

Whether the information will be shared with other institutions.

Whether samples or data will be transferred abroad.

Whether future research use is contemplated.

Consent for one research project should not automatically be treated as unrestricted permission for every future scientific purpose.

9.2 Genetic discrimination

Genetic information may expose vulnerable participants to discrimination in employment, insurance, education or social relationships.

Researchers should therefore implement confidentiality procedures, access controls, secure storage and appropriate restrictions on disclosure.

9.3 CNDP oversight

The CNDP provides a regulatory mechanism for personal-data processing, including procedures for prior declarations and authorisations where required.

A particularly relevant development occurred on 11 May 2026, when the CNDP presented 17 recommendations concerning personal-data protection and genomic information following approximately two and a half years of expert work.

This development demonstrates the increasing importance of genomic privacy in Morocco's regulatory framework. The recommendations should not, however, be confused with a new enacted statute.

CNDP+1

10. Ethical Review and Institutional Accountability

Moroccan Law No. 28-13 establishes Regional Committees for the Protection of Persons Participating in Biomedical Research.

Article 17: Regional ethical committees

These committees examine biomedical research projects and provide opinions, particularly on ethical matters.

Article 18: Multidisciplinary composition

Their composition must take account of pluralism and multidisciplinary expertise, including representatives from:

Medicine.

Biology.

Pharmacy.

Ethics.

Social sciences.

Psychology.

Religious studies.

Law.

A research sponsor or its delegate cannot become a member of the relevant regional committee.

Ma Loi

Importance for vulnerable populations

Ethical review should consider whether:

Vulnerable individuals are being recruited unnecessarily.

Participants are exposed to disproportionate risks.

Consent procedures are understandable.

Researchers have adequately protected confidentiality.

The research has a scientifically defensible objective.

Participants have access to appropriate medical supervision.

The benefits and burdens of research are distributed fairly.

Important regulatory development in 2026

Morocco adopted Decree No. 2.26.223 of 30 April 2026, amending and supplementing Decree No. 2.20.326 of 5 April 2021, which implements Law No. 28-13.

The amendments include:

Changes to the institutional authorisation structure following the establishment of the Moroccan Agency for Medicines and Health Products.

Authority for the Agency's Director to grant, suspend and withdraw authorisations for interventional biomedical research, following the opinion of an independent advisory committee.

Changes to the institutional placement of regional protection committees.

Digital submission of research authorisation applications.

An expedited procedure for public-health emergencies.

Publication of authorised research projects on the Agency's website.

These changes are important because they strengthen the administrative oversight of research projects and improve transparency. Emergency procedures should not be interpreted as eliminating participants' fundamental protections.

Eastlaws+2

11. Liability and Compensation for Research-Related Harm

Protection of vulnerable participants must include remedies when research causes injury.

Article 34 of Law No. 28-13 provides an important compensation mechanism.

Under this provision:

The sponsor is responsible for damage affecting a participant's health during or after biomedical research where a causal relationship with the research is established.

The injured participant is entitled to full compensation.

In the event of death, the participant's successors may claim compensation.

The sponsor must obtain and renew civil liability insurance covering the research.

The insurance must also cover the civil liability of investigators and other persons involved in the research.

The administration may suspend or withdraw research authorisation where the required insurance is not obtained or renewed.

Ma Loi

Example: A vulnerable patient participates in an experimental cellular therapy trial and subsequently suffers serious complications attributable to the research.

Article 34 provides a statutory basis for claiming compensation, provided the required causal connection is established.

This is particularly significant because vulnerable participants may lack the financial resources to pursue complicated scientific litigation. Insurance and sponsor responsibility help reduce the practical obstacles to obtaining compensation.

12. Other Relevant Moroccan Legislation

The safeguards are not limited to Law No. 28-13.

The Ministry of Health's official legislation directory identifies these important medical regulatory instruments.

sante.gov.ma

13. Relevant Case Laws and Judicial Principles

An important distinction is necessary when discussing case law in Morocco: there is a difference between a judgment delivered by a Moroccan court and a foreign judgment that provides persuasive comparative guidance.

I have not identified a publicly reported Moroccan appellate or Supreme Court judgment specifically interpreting Articles 12, 16 or 34 of Law No. 28-13 in the context of vulnerable biotechnology research. The following cases therefore provide comparative judicial principles rather than binding Moroccan precedents.

13.1 V.C. v. Slovakia (2011), European Court of Human Rights

Subject: Involuntary sterilisation and informed consent.

The applicant underwent sterilisation in a hospital without having given valid informed consent.

The European Court of Human Rights found violations of Articles 3 and 8 of the European Convention on Human Rights.

Legal principle:

Medical interventions affecting reproductive autonomy must respect personal dignity, physical integrity and informed consent.

Relevance to Morocco:

This judgment provides useful guidance for biotechnology involving reproductive genetics, fertility treatments, genetic screening and experimental reproductive procedures.

Researchers must not exploit the vulnerability of patients to obtain consent for procedures they do not properly understand.

13.2 Glass v. United Kingdom (2004), European Court of Human Rights

Subject: Medical treatment of a child and parental decision-making.

The case concerned medical treatment administered to a seriously ill child despite disagreement between the medical professionals and the child's mother.

The Court found a violation of Article 8 because the interference with family and private life had not been justified under the Convention.

Legal principle:

Medical professionals must respect the applicable legal framework governing parental involvement, medical decision-making and the rights of children.

Relevance to Morocco:

The case is useful when considering Article 12 of Law No. 28-13, particularly where researchers seek parental consent for research involving minors.

Parental authorisation should not become an instrument for disregarding a child's own legally relevant wishes.

13.3 M.A.K. and R.K. v. United Kingdom (2010), European Court of Human Rights

Subject: Medical testing of a child without proper parental involvement.

The case concerned medical examinations and testing conducted on a child without the required parental consent.

The Court found violations of Article 8 of the European Convention on Human Rights.

Legal principle:

Medical examinations involving children must respect the applicable requirements of consent and private life.

Relevance to Morocco:

This decision is relevant to genetic testing of minors, paediatric biotechnology research and the collection of children's biological samples.

It illustrates why research institutions should establish clear consent and authorisation procedures before undertaking medical investigations.

13.4 Hristozov and Others v. Bulgaria (2012), European Court of Human Rights

Subject: Access to experimental cancer treatment.

The applicants were seriously ill cancer patients seeking access to experimental medicinal products that had not received the necessary marketing authorisation.

The European Court examined the applicants' arguments under the right to life and respect for private life. It did not find a violation of the relevant Convention provisions.

Legal principle:

The desire of seriously ill patients to access experimental treatments must be considered alongside the State's responsibility to regulate medicines and protect public health.

Relevance to Morocco:

The decision is useful when evaluating vulnerable patients recruited for experimental gene therapies, cellular treatments and other unapproved biotechnology interventions.

A patient's desperation for treatment should not be used to justify inadequate scientific evidence, insufficient disclosure or inappropriate research practices.

13.5 International ethical and legal standards

In addition to judicial decisions, several international instruments provide important interpretative guidance:

These instruments should be distinguished according to their legal status: international treaties binding on Morocco are different from non-binding ethical declarations and comparative judicial authorities.

14. Major Regulatory Challenges in Morocco

Despite the existence of a statutory framework, several practical challenges remain.

14.1 Economic vulnerability

Poor patients may agree to participate in experimental research because they cannot afford conventional treatment.

This creates a risk that financial hardship will undermine voluntary participation.

Suggested legal response: Independent consent verification, reasonable reimbursement policies and protection against research-related financial exploitation.

14.2 Limited scientific literacy

Genetic engineering, genome sequencing and stem-cell technologies involve technical concepts that participants may find difficult to understand.

Suggested legal response: Simplified consent documents, accessible explanations and independent counselling.

14.3 Genetic privacy and family disclosure

Genetic information can reveal sensitive information about relatives who have never directly participated in research.

Suggested legal response: Strict confidentiality, purpose limitation, controlled access and clearly defined policies for incidental findings.

14.4 Cross-border biotechnology research

International pharmaceutical companies may recruit Moroccan participants while transferring biological samples and genomic data to foreign laboratories.

This creates questions involving:

International data transfers.

Foreign research institutions.

Ownership and future use of biological samples.

Confidentiality.

Compensation for research-related injuries.

Foreign sponsor accountability.

Suggested legal response: Stronger cross-border agreements, transparent research protocols and compliance with Moroccan data-protection requirements.

14.5 Weak representation of vulnerable communities

Children, persons with disabilities and economically disadvantaged communities may not have adequate representation in research governance.

Suggested legal response: Greater community participation, independent advocacy and multidisciplinary ethical review.

15. Hypothetical Legal Case Study

Facts:

A foreign biotechnology company collaborates with a Moroccan research hospital to conduct genetic research involving 200 children from economically disadvantaged families.

The company collects blood samples and DNA profiles. Parents are asked to sign consent forms, but the forms do not explain that the genetic information will be transferred to a foreign laboratory and used in future commercial research.

Some children object to participation, but the researchers continue collecting samples because their parents have signed the forms.

Legal issues:

Whether parental consent is sufficient under Article 12 of Law No. 28-13.

Whether children's objections have been properly respected.

Whether the research satisfies the special requirements for non-therapeutic research.

Whether genetic information is being processed lawfully under Law No. 09-08.

Whether international data transfers comply with Moroccan requirements.

Whether the regional ethics committee properly examined the research protocol.

Possible legal consequences:

Regulatory examination of the research authorisation.

Suspension or withdrawal of research authorisation where legally justified.

Investigation of unlawful personal-data processing.

Civil liability where participants suffer compensable harm.

Compensation under Article 34 where its requirements are satisfied.

Further action against responsible persons where an applicable legal violation is established.

Legal conclusion: Parental permission cannot automatically validate every research activity involving children. The statutory restrictions, the child's ability to express a will, the research purpose and the privacy obligations must all be independently examined.

16. Recommendations for Strengthening Moroccan Biotechnology Law

The following reforms could improve the protection of vulnerable research participants.

1. Special genetic-research legislation: Develop more detailed rules for genetic testing, genome editing and long-term storage of human biological samples.

2. Independent participant advocates: Provide independent support for children, persons with disabilities and economically disadvantaged participants.

3. Stronger consent procedures: Introduce standardised, understandable and accessible consent documents.

4. Protection against commercial exploitation: Establish clearer restrictions on the commercial use of biological samples and genetic information.

5. Long-term monitoring: Require appropriate monitoring of participants after experimental biotechnology interventions.

6. Transparent compensation mechanisms: Improve access to compensation and independent legal assistance for injured research participants.

7. International research supervision: Strengthen oversight of foreign sponsors and international transfers of genetic data and biological materials.

8. Community participation: Involve affected communities in decisions concerning genetic databases and population-level biotechnology studies.

9. Research transparency: Improve public access to information about approved research, ethical review and participant-protection procedures.

10. Judicial accountability: Encourage publication of anonymised judgments involving biomedical research, informed consent and research-related injuries.

17. Conclusion

The regulation of vulnerable population safeguards in biotechnology research in Morocco is founded principally on constitutional human-rights protections, Law No. 28-13 of 2015 and Law No. 09-08 of 2009.

Law No. 28-13 establishes particularly important protections through informed consent, restrictions on research involving minors and legally protected adults, prohibitions concerning certain detained and compulsorily hospitalised individuals, regional ethical review and sponsor liability.

The 2026 amendments to the implementing framework also demonstrate the continuing development of Morocco's biomedical research regulatory institutions.

However, effective protection requires more than formal legislation. It requires meaningful consent, independent supervision, genetic privacy, protection against economic exploitation and accessible remedies for research-related harm.

Ultimately, the dignity and rights of vulnerable research participants must take priority over commercial interests and scientific convenience.

18. Principal Legal Sources and Research References

Constitution of the Kingdom of Morocco, 2011.

Moroccan Ministry of Health – Biomedical Research Legislation.

Law No. 28-13 – Article 12.

Law No. 28-13 – Article 4.

Law No. 28-13 – Article 34.

Law No. 09-08 on Personal Data Protection.

Decree No. 2.26.223 of 30 April 2026.

Moroccan CNDP – Data Protection Legislation.

United Nations – Morocco's explanation of Law No. 28-13.

Law No. 28-13 – Additional statutory provisions.

Research note: For academic or legal citation, the official Arabic text published in the Moroccan Bulletin Officiel should be checked where there is any discrepancy with an unofficial translation. The foreign cases discussed above are comparative authorities, not Moroccan precedents.